POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER).
Potassium is the major intracellular cation, essential for maintenance of normal cell function, nerve impulse transmission, and muscle contraction. Replacement therapy restores potassium levels in hypokalemia.
| Metabolism | Potassium is not metabolized; it is absorbed from the gastrointestinal tract and primarily excreted by the kidneys. |
| Excretion | Primarily renal (90%), with fecal elimination accounting for approximately 10%. Excretion is via glomerular filtration, with tubular reabsorption and secretion adjusting potassium balance. |
| Half-life | Not applicable as potassium is an endogenous ion; however, the biological half-life for serum potassium redistribution and excretion is approximately 1-1.5 hours in individuals with normal renal function. In renal impairment, half-life may be prolonged and requires dose adjustment. |
| Protein binding | Not significantly protein-bound (<5%). |
| Volume of Distribution | Approximately 0.5 L/kg in healthy individuals, reflecting distribution primarily in intracellular and extracellular fluid. Neonates may have a higher Vd (up to 0.6 L/kg). |
| Bioavailability | Oral: approximately 90-100% for immediate-release formulations; sustained-release forms have slightly lower bioavailability but are still 80-100%. Intravenous: 100%. |
| Onset of Action | Intravenous: onset within minutes for ECG effects; oral: onset of action typically within 30 minutes to 1 hour for serum potassium elevation. |
| Duration of Action | Duration is dependent on ongoing potassium balance; for acute intravenous correction, effects may last 2-4 hours after infusion; oral sustained-release forms provide action over 6-8 hours. |
20 mEq intravenously over 1 hour, repeated as needed based on serum potassium levels. Maximum infusion rate 10 mEq/hour. Maximum daily dose 200 mEq.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 50% or monitor serum potassium closely. GFR <30 mL/min: avoid use or use with extreme caution (maximum 10 mEq/h, monitor ECG and K+). |
| Liver impairment | No specific adjustment required for Child-Pugh A or B. Child-Pugh C: monitor serum potassium closely as risk of hyperkalemia may be increased due to impaired potassium handling. |
| Pediatric use | 0.5-1 mEq/kg/dose intravenously, maximum 20 mEq/dose, infused at a rate not exceeding 0.5 mEq/kg/hour. Repeat based on serum potassium levels. |
| Geriatric use | Initiate at lower end of dosing range (e.g., 10 mEq intravenously over 1 hour). Monitor renal function and serum potassium frequently due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER).
| Breastfeeding | Compatible with breastfeeding; potassium is a normal component of breast milk. M/P ratio not reported; exogenous potassium is unlikely to affect infant serum levels due to renal regulation. Avoid only if maternal hyperkalemia present. |
| Teratogenic Risk | No evidence of teratogenic risk; potassium chloride is an essential electrolyte. First trimester: no known embryotoxic effects. Second and third trimesters: no known fetal harm, but maternal hyperkalemia can cause fetal arrhythmias and neonatal depression. High doses may affect fetal acid-base balance. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or azotemia","Untreated Addison's disease","Severe hemolytic reactions","Acute dehydration","Concurrent use with potassium-sparing diuretics or ACE inhibitors that may increase hyperkalemia risk"]
| Precautions | ["Administer with caution in patients with renal impairment, severe burns, or adrenal insufficiency.","Too rapid administration may cause fatal hyperkalemia and cardiac arrest.","Monitor serum potassium levels during therapy.","Do not administer unless solution is clear and container undamaged."] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium, renal function, and ECG. In pregnancy, monitor for signs of hyperkalemia (weakness, arrhythmias). Fetal monitoring indicated only with maternal severe electrolyte disturbances or arrhythmias. |
| Fertility Effects | No known adverse effects on human fertility. Potassium homeostasis is essential for reproductive function; no evidence of fertility impairment with therapeutic use. |